Benefit of Inactivated Influenza Vaccine in Infants in Iran: A Community based Randomized Control Trial

Document Type : Original Article

Authors

1 MD, Department of Biostatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 PhD, Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 MD-MpH, School of Health, Management & Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4 MD, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Influenza in infants and young children is a major medical problem which causes excess medical visits, antibiotic prescriptions and hospitalization even in otherwise healthy children. Many of the developed countries have recommended influenza vaccination for all children (>6month old), but the economic benefit of this strategy is not clear especially for developing countries.

Objectives: To find the difference in the incidence of influenza-like illness (ILI) and economic cost related to it between TIV vaccinated and non-vaccinated infants in Mashhad, Iran.

Methods: This was a community randomized controlled trial which was started in November 2005 and ended up at May 2006. Each of the study and control groups were composed of 500 infants between 6 month and 20 months old who were brought for routine vaccination. The study group was given two doses of TIV; the control group received routine care without any extra intervention. Both groups were followed by monthly telephone calls (up to six months after the vaccination) and were asked about signs and symptoms of flu like illnesses and any cost related to them. SPSS 11.5 was used for statistical analysis, P<0.05 is considered as statistically significant.

Results: There was no significant difference in the monthly occurrence of ILI between the vaccinated and non-vaccinated groups (P: 0.06-0.97). The costs related to ILI were similar between vaccine and control groups, except for physicians visit cost in the third month, which was more in the control group (P<0.05).

Conclusion: In influenza season of 2005-06, TIV vaccination did not decrease the rate of influenza-like illnesses and was not cost saving in infants (6- 20 months old) in Mashhad.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1.Principi N, Esposito S. Are we ready for universal influenza vaccination in pediatrics? Lancet Infect Dis. 2004;4(2):75-83. [PubMed: 14871631].
https://doi.org/10.1016/S1473-3099(04)00926-0
PMid:14871631
 
2. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2018;2:CD004879. [PubMed: 29388195].
https://doi.org/10.1002/14651858.CD004879.pub5
PMid:29388195
 
3. Usonis, V, Anca I, André F, Chlibek R, Ivaskeviciene I, Mangarov A, et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children. BMC Infect Dis. 2010;10:168.. [PubMed: 20546586].
https://doi.org/10.1186/1471-2334-10-168
PMid:20546586 PMCid:PMC2905419
 
4. Statement, Australian Technical Advisory Group on Immunisation (ATAGI). Clinical advice for immunization providers regarding the administration of 2012 trivalent seasonal influenza vaccines. Australia: Department of Health and Ageing Australian Government; 2012.
 
5. Halloran ME, Piedra PA, Longini IM Jr, Gaglani MJ, Schmotzer B, Fewlass C, et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007;25(20):4038-45. [PubMed: 17395338].
https://doi.org/10.1016/j.vaccine.2007.02.060
PMid:17395338 PMCid:PMC2883284
 
6. Heikkinen T, Heinonen S. Effectiveness and safety of influenza vaccination in children: European perspective. Vaccine. 2011; 29(43):7529-34. [PubMed:21820481].
https://doi.org/10.1016/j.vaccine.2011.08.011
PMid:21820481
 
7. Patrick O, Ron D, Jachen M, Jose Antonio N, Pekka N, Caraten P, et al. Technical report of the scientific panel on vaccines and immunization infant and children seasonal immunization against influenza on a routine basis during inter-pandemic period. Available at: URL: https://ecdc.europa.eu/sites/portal/ files/media/en/publications/Publications/0701_TER_Scientifi c_Panel_on_Vaccines_and_Immunisation.pdf; 2007.
 
8. Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine. 2006;24(5):629-35.. [PubMed: 16157429].
https://doi.org/10.1016/j.vaccine.2005.08.054
PMid:16157429
 
9. Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003;290(12):1608-16. [PubMed: 14506120].
https://doi.org/10.1001/jama.290.12.1608
PMid:14506120
 
10. Cochran LW, Black S, Klein NP, Dekker CL, Lewis E, Reingold AL. Vaccine effectiveness against laboratory-confirmed influenza in infants: a matched case control study. Hum Vaccine. Hum Vaccine. 2010;6:9. [PubMed: 20855940].
https://doi.org/10.4161/hv.6.9.12470
PMid:20855940
 
11. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis. 2011;11(1):23-9. [PubMed: 21106443].
https://doi.org/10.1016/S1473-3099(10)70255-3
PMid:21106443
 
12. Katayose M, Hosoya M, Haneda T, Yamaguchi H, Kawasaki Y, Sato M, et al. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine. 2011;29(9):1844-9. [PubMed: 21195802].
https://doi.org/10.1016/j.vaccine.2010.12.049
PMid:21195802
 
13. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8years of age, with 1 vs 2 doses. Pediatrics. 2005;116(1):153-9. [PubMed: 15995046].
https://doi.org/10.1542/peds.2005-0049
PMid:15995046
 
14. Allison MA, Daley MF, Crane LA, Barrow J, Beaty BL, Allred N, et al. Influenza vaccine effectiveness in healthy 6- to 21-monthold children during the 2003-2004 season. J Pediatr. 2006; 149(6):755-62.. [PubMed:17137887].
https://doi.org/10.1016/j.jpeds.2006.06.036
PMid:17137887
 
15. Lee VJ, Tok MY, Chow VT, Phua KH, Ooi EE, Tambyah PA, et al. Economic analysis of pandemic influenza vaccination strategies in Singapore. PLoS One. 2009;4(9):e7108. [PubMed: 19771173].
https://doi.org/10.1371/journal.pone.0007108
PMid:19771173 PMCid:PMC2743808
 
16. Porras-Ramírez A, Alvis-Guzmán N, Rico-Mendoza A, AlvisEstrada L, Castañeda-Orjuela CA, Velandia-González MP, et al. Cost effectiveness of influenza vaccination in children under 2 years old and elderly in Colombia. Rev Salud Publica (Bogota). 2009;11(5):689-99. [PubMed: 20339595].
https://doi.org/10.1590/S0124-00642009000500002
PMid:20339595
 
17. Dayan GH, Nguyen VH, Debbag R, Gómez R, Wood SC. Costeffectiveness of influenza vaccination in high-risk children in Argentina. Vaccine. 2001;19(30):4204-13 [PubMed: 11457546].
https://doi.org/10.1016/S0264-410X(01)00160-8
PMid:11457546
 
18. Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ. Costeffectiveness study on influenza prevention in Hong Kong. Health Policy. 2001;56(3):215-34. [PubMed: 11399347].
https://doi.org/10.1016/S0168-8510(00)00140-8
PMid:11399347
Razavi International Journal of Medicine
Volume 6, Issue 4
October 2018

Files

Share

How to cite

Statistics